New PET tracer could spot hidden heart scarring in rare amyloidosis

NCT ID NCT07549841

Not yet recruiting Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a special radioactive tracer called [68Ga]Ga-FAPI-46 for PET scans in 40 people with transthyretin cardiac amyloidosis (ATTR-CM), a condition where abnormal proteins build up in the heart. The goal is to see if this scan can measure scar-like activity in the heart muscle and help doctors tell how advanced the disease is or if it's getting worse. If it works, it could lead to better staging and personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [68Ga]Ga-FAPI-46 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors better stage the disease and identify which patients are worsening, leading to more personalized treatment.
What could go wrong: This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The tracer's ability to predict progression needs further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

Chu Nantes

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.